Navigation Links
Smaller, faster trials can improve cancer patient survival

Stockholm, Sweden: With the advent of personalised medicine, gains in cancer survival over the long term could be improved by running smaller, faster trials with less stringent evidence criteria, a researcher told the 2011 European Multidisciplinary Cancer Congress [1] today (Monday 26 Sept).

The introduction of targeted treatments means the traditional large-scale clinical trial is not always the most effective way of getting new treatments to cancer patients who need them, said Dr. Marie-Ccile Le Deley, Associate Professor of Clinical Epidemiology and Biostatistics at the Institut Gustave-Roussy, Villejuif, France. The increased knowledge of tumour biology has meant that common cancers are more and more frequently recognised as consisting of small subsets with particular abnormalities. These abnormalities might be targeted by specific therapies, but the ability to test many of the promising agents available is hindered by the need to invest many resources into running a single large trial over many years, she said.

Working with colleagues at The Mayo Clinic in Rochester, Minnesota, USA, Dr. Le Deley simulated a series of two-treatment superiority trials (where a new treatment is compared with the existing standard therapy), taking place over 15 years and using different design parameters. These included the number of trials performed during the period, and the criteria used to adopt an experimental treatment as the new standard. The researchers used these studies to estimate, for different strategies, the survival improvements that could be expected over a 15-year research period.

"We found that there were important gains in survival attributable to a strategy of conducting more trials with smaller sample sizes and relaxed evidential criteria compared with those required under traditional trial designs," said Dr. Le Deley. "The downside of this approach is that we also reduce the certainty of the findings: we might select as a new temporary standard a treatment that does not work better than the existing best therapy, but the fact that we will conduct many more trials will allow such errors to be quickly remedied.

"Considering that many new targeted agents have fewer safety issues than the older cytotoxic (cell killing) treatments, we feel that the risk of accepting a few therapies that offer no benefit, but with a very low chance of a truly poorer outcome, for a greater long-term benefit at the end seems reasonable. The possibility of a small number of backward steps in the series of trials should not lead us to discard the whole process. The classical, large sample-size clinical trials are designed to avoid wrong decisions, but take a very long time to reach a definitive result when the disease is rare."

In rare diseases, the ability to pursue many of the promising agents available for clinical testing is hindered by the need to invest much effort in a single direction by running a large trial over many years, the researchers say. However, they believe that statisticians and regulators may be more difficult to convince of the need for change. "The culture within these groups is very risk-averse," said Dr. Le Deley. "Their conservative approach is reasonable; the higher the strength of evidence, the lower the risk of wrong decision. But in rare diseases, which could include many small subsets of cancers, this approach is counterproductive as soon as many new agents become available for clinical testing. We need a more flexible process to cater for this situation."

Dr Le Deley makes it clear that her recommendation to decrease the sample size and relax the decision criteria makes sense only if there is no way to increase the trial accrual rate, and thus that the proposal should not be taken as an encouragement to abandon collaborative projects with potential for broad participation. The traditional, large-scale clinical trial will still be needed, but smaller, targeted trials should be allowed where appropriate, and these could lead to quicker results, and in the long term, greater gains, say the researchers.

"The other main benefit of this strategy is that it allows for the testing of a greater number of treatments. Our approach of viewing a succession of clinical trials as a whole, as opposed to looking at them trial by trial, may help us to move forward. Our work has shown that the current risk-averse trial design strategy is not always appropriate as patient populations become more and more specific, and hence smaller," said Dr. Le Deley. "We hope that regulators will take this into account and re-examine their procedures in the interests of getting new, effective treatments to selected groups of patients as quickly as possible."

"The arrival of personalised medicine means that we will have to change our thinking and ways of doing many things, and trials are just one example of this. The problems arising from the drafting and implementation of the Clinical Trials Directive have shown clearly that oncologists need to be looking ahead and planning for impending changes at all times," said ECCO President, Professor Michael Baumann.

"That is why ECCO is pushing ahead with developing European cancer policy through our oncopolicy programme. We want to make sure that advances in treatment and care get out of the laboratory to the patient as soon as we can, and our multidisciplinary status means that we are particularly qualified to represent the views of all those involved in cancer patients, healthcare professionals, and scientists to policymakers."


Contact: Mary Rice
ECCO-the European CanCer Organisation

Related medicine news :

1. Faster progress through puberty linked to behavior problems
2. Language speed versus efficiency: Is faster better?
3. Faster Way to Treat Partners of Women With STDs Urged: Experts
4. Study on football: Women get up faster
5. Hammock Effect May Help Adults Fall Asleep Faster
6. Faster Transition From CPR to Defibrillator May Save Lives
7. Limiting carbs, not calories, reduces liver fat faster, UT Southwestern researchers find
8. Radiation at time of lumpectomy may offer faster, more precise treatment for breast cancer patients
9. Narrowed Leg Arteries Disable Women Faster Than Men: Study
10. Younger immigrants adjust to a new culture faster than do older immigrants
11. High levels of circulating DNA may signal faster progression of lung cancer
Post Your Comments:
(Date:11/29/2015)... Raleigh, NC (PRWEB) , ... November 29, 2015 , ... ... calling on their colleagues to recognize the signs of mesothelioma and push for a ... the report on its website. Click here to read it now. ...
(Date:11/28/2015)... ... November 28, 2015 , ... StatRad ... has added Chris Hafey and Claude Hooton to its board of directors. The ... North America (RSNA) 2015 Annual Meeting and continues to strategically transform its focus ...
(Date:11/28/2015)... , ... November 28, 2015 , ... Pixel Film Studios ... media panels to choose from, the possibilities are endless. Users have full control over ... the ProPanel: Pulse masking effects, users are sure to get heads to turn. , ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 15th ... are handling security in light of the recent terrorist attacks in Paris, other cities ... stop an attack from reaching U.S. soil. Especially around special events that may be ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Care Market by Type (Dressings, Therapy Devices, Active Wound ... Out-Patient Facility), and Geography - Global Forecast to 2020" ... --> --> The purpose of this ... of the global advanced wound care market. It involves ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... 2015  The American Academy of Pediatrics (AAP), ... the March of Dimes cheered today,s signature into ... Act of 2015 (S.799), which takes much-needed ... exposed to drugs, such as opioids, and to ... three organizations have worked together leading advocacy efforts ...
Breaking Medicine Technology: